- Home
- WSC vs TVTX Comparison
WSC vs TVTX Comparison
Compare WSC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSC
- TVTX
- Stock Information
- Founded
- WSC 1944
- TVTX 2008
- Country
- WSC United States
- TVTX United States
- Employees
- WSC N/A
- TVTX N/A
- Industry
- WSC Misc Corporate Leasing Services
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- WSC Industrials
- TVTX Health Care
- Exchange
- WSC Nasdaq
- TVTX Nasdaq
- Market Cap
- WSC 2.8B
- TVTX 3.1B
- IPO Year
- WSC N/A
- TVTX N/A
- Fundamental
- Price
- WSC $17.60
- TVTX $35.61
- Analyst Decision
- WSC Buy
- TVTX Strong Buy
- Analyst Count
- WSC 8
- TVTX 15
- Target Price
- WSC $26.00
- TVTX $37.21
- AVG Volume (30 Days)
- WSC 4.3M
- TVTX 2.1M
- Earning Date
- WSC 11-06-2025
- TVTX 10-30-2025
- Dividend Yield
- WSC 1.58%
- TVTX N/A
- EPS Growth
- WSC 816.06
- TVTX N/A
- EPS
- WSC 1.20
- TVTX N/A
- Revenue
- WSC $2,317,990,000.00
- TVTX $435,826,000.00
- Revenue This Year
- WSC N/A
- TVTX $108.68
- Revenue Next Year
- WSC $2.83
- TVTX $40.23
- P/E Ratio
- WSC $14.79
- TVTX N/A
- Revenue Growth
- WSC N/A
- TVTX 114.22
- 52 Week Low
- WSC $14.91
- TVTX $12.91
- 52 Week High
- WSC $39.81
- TVTX $36.87
- Technical
- Relative Strength Index (RSI)
- WSC 41.54
- TVTX 63.87
- Support Level
- WSC $14.91
- TVTX $34.18
- Resistance Level
- WSC $17.95
- TVTX $36.87
- Average True Range (ATR)
- WSC 1.12
- TVTX 1.87
- MACD
- WSC -0.07
- TVTX -0.23
- Stochastic Oscillator
- WSC 43.74
- TVTX 78.66
About WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.